Skyrizi 180 MG/1.2 ML on-body 1.2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0MD3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,467
Award facts
- Contract value 100% obligated
- $12,467.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $12,467.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 180 MG/1.2 ML on-body autoinjector units on January 21, 2026. This contract represents a child delivery order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99 million through December 2031. The award carries no set-aside designation and will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of February 11, 2026. SKYRIZI (risankizumab) is a biologic medication used to treat moderate to severe plaque psoriasis and other inflammatory conditions, making this delivery order part of DLA's broader pharmaceutical supply chain supporting military healthcare programs.
This delivery order exemplifies the Defense Logistics Agency's ongoing relationship with Cencora/AmerisourceBergen for pharmaceutical procurement across multiple therapeutic domains. As a major pharmaceutical distributor serving federal medical systems, AmerisourceBergen maintains a robust portfolio of competitively awarded contracts with DLA and the Defense Health Agency, delivering specialty medications, branded and generic drugs, and medical devices to support military treatment facilities and veteran healthcare programs globally. The firm fixed-price structure and short delivery timeline reflect the critical nature of pharmaceutical supply management within the federal healthcare system.
Quick answers
Who was awarded contract SPE2DR26F0MD3?
SPE2DR26F0MD3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26F0MD3 worth?
The government has obligated $12,467 on SPE2DR26F0MD3.
Is contract SPE2DR26F0MD3 an order under another contract?
Yes. SPE2DR26F0MD3 is a delivery order under SPE2DR25D3007, an indefinite delivery contract.
Was contract SPE2DR26F0MD3 competed?
The extent of competition for SPE2DR26F0MD3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award